KRAS and colorectal carcinoma: CRC molecular subtype is associated with drug resistance—MSI is linked with resistance to 5-Fluorouracil (5-FU) and CIMP may also imply a lack of benefit from this therapy [4], while KRAS mutations confer resistance to cetuximab [6,7].